ArticleOncotarget2013
Selective anticancer agents suppress aging in Drosophila.
Article in Oncotarget, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 46 citations in OpenAlex.
- Diet-dependent, beneficial and adverse effects of rapamycin on life span of Drosophila melanogaster.GeroScience · 2026Article
- Procyanidin A1 from Peanut Skin Exerts Anti-Aging Effects and Attenuates Senescence via Antioxidative Stress and Autophagy Induction.Antioxidants (Basel, Switzerland) · 2025Article
- Effects of Target of Rapamycin and Phosphatidylinositol 3-Kinase Inhibitors and Other Autophagy-Related Supplements on Life Span inInternational journal of molecular sciences · 2024Article
- Combinatorial interventions in aging.Nature aging · 2023Review
- Therapeutic Antiaging Strategies.Biomedicines · 2022Review
- Molecular mechanisms of exceptional lifespan increase of Drosophila melanogaster with different genotypes after combinations of pro-longevity interventions.Communications biology · 2022Article
- Innate and Adaptive Immunity in Aging and Longevity: The Foundation of Resilience.Aging and disease · 2020Article
- Article
- Transcriptomics-Based Screening Identifies Pharmacological Inhibition of Hsp90 as a Means to Defer Aging.Cell reports · 2019Article
- Article
- Comparative transcriptomics across 14 Drosophila species reveals signatures of longevity.Aging cell · 2018Article
- Article
- Current Perspective in the Discovery of Anti-aging Agents from Natural Products.Natural products and bioprospecting · 2017Review
- From rapalogs to anti-aging formula.Oncotarget · 2017Review
- Geroprotectors: A Unified Concept and Screening Approaches.Aging and disease · 2017Review
- Gerosuppression by pan-mTOR inhibitors.Aging · 2016Article
- Effects of Abies sibirica terpenes on cancer- and aging-associated pathways in human cells.Oncotarget · 2016Article
- Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic.Aging cell · 2016Review
- BLAT2DOLite: An Online System for Identifying Significant Relationships between Genetic Sequences and Diseases.PloS one · 2016Article
- Influence of non-steroidal anti-inflammatory drugs on Drosophila melanogaster longevity.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations of the PI3K, TOR, iNOS, and NF-κB genes increase lifespan of model organisms and reduce the risk of some aging-associated diseases. We studied the effects of inhibitors of PI3K (wortmannin), TOR (rapamycin), iNOS (1400W), NF-κB (pyrrolidin dithiocarbamate and QNZ), and the combined effects of inhibitors: PI3K (wortmannin) and TOR (rapamycin), NF-κB (pyrrolidin dithiocarbamates) and PI3K (wortmannin), NF-κB (pyrrolidine dithiocarbamates) and TOR (rapamycin) on Drosophila melanogaster lifespan and quality of life (locomotor activity and fertility). Our data demonstrate that pharmacological inhibition of PI3K, TOR, NF-κB, and iNOS increases lifespan of Drosophila without decreasing quality of life. The greatest lifespan expanding effect was achieved by a combination of rapamycin (5 μM) and wortmannin (5 μM) (by 23.4%). The bioinformatic analysis (KEGG, REACTOME.PATH, DOLite, and GO.BP) showed the greatest aging-suppressor activity of rapamycin, consistent with experimental data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.